 Genotype 6 HCV HCV-6 is common in parts of South-East Asia, in particular Vietnam. There is a small but growing population of immigrant patients with chronic HCV-6 in Australia. The current standard-of-care treatment SOC for chronic HCV-6 infection is peg-interferon-α PEG-IFN and ribavirin RBV therapy for 48 weeks. The available data evaluating treatment outcome suggests that SVR rates are intermediate between those of HCV-1 and HCV-23. There is a medical need for novel therapies that might increase SVR rates andor allow shortened treatment duration. 